Souwer Ibo H, Bor Jacobus Hj, Smits Paul, Lagro-Janssen Antoine Lm
Department of Primary and Community Care, Gender and Women's Health.
Department of Primary and Community Care.
Br J Gen Pract. 2017 Mar;67(656):e187-e193. doi: 10.3399/bjgp17X689413. Epub 2017 Feb 13.
GPs prescribe topical corticosteroids to patients with chronic chilblains despite poor evidence for their effectiveness. The authors of the current study therefore decided to assess the effectiveness of topical steroids in a primary care setting.
To assess the effectiveness of topical application of betamethasone valerate 0.1% cream in patients with chronic chilblains.
A placebo-controlled, double-blind, crossover, randomised clinical trial in a Dutch primary care setting.
The study population consisted of 34 participants suffering from chronic chilblains. Intervention was topical application of betamethasone valerate 0.1% cream twice a day for 6 weeks compared with placebo. Primary outcome was the visual analogue scale on complaints (VOC). Secondary outcome was the visual analogue scale on disability (VOD). Both were assessed with a diary of daily scores on a 100 mm visual analogue scale. The authors took ambient temperatures into account, checked for a carry-over effect, performed additional analysis, and monitored adverse effects.
On the primary outcome mean VOC, there was a difference of 0.56 mm (95% confidence interval [CI] = -2.88 to 3.99 mm) in favour of placebo ( = 0.744). On the secondary outcome mean VOD, there was a difference of 0.88 mm (95% CI = -2.22 to 3.98 mm) in favour of placebo ( = 0.567). This study found no carry-over effect and no adverse effects.
In this study, topical betamethasone was not superior to placebo in the treatment of chronic chilblains. Topical betamethasone should not be used for chronic chilblains without new evidence.
尽管缺乏有效性证据,全科医生仍会为慢性冻疮患者开具局部用皮质类固醇药物。因此,本研究的作者决定在初级医疗环境中评估局部用类固醇药物的有效性。
评估0.1%戊酸倍他米松乳膏局部应用于慢性冻疮患者的有效性。
在荷兰初级医疗环境中进行的一项安慰剂对照、双盲、交叉、随机临床试验。
研究人群包括34名患有慢性冻疮的参与者。干预措施为每天两次局部应用0.1%戊酸倍他米松乳膏,持续6周,与安慰剂进行比较。主要结局是症状视觉模拟量表(VOC)。次要结局是残疾视觉模拟量表(VOD)。两者均通过在100毫米视觉模拟量表上记录每日得分的日记进行评估。作者考虑了环境温度,检查了残留效应,进行了额外分析,并监测了不良反应。
在主要结局平均VOC方面,有利于安慰剂的差异为0.56毫米(95%置信区间[CI]= -2.88至3.99毫米)(P =0.744)。在次要结局平均VOD方面,有利于安慰剂的差异为0.88毫米(95% CI = -2.22至3.98毫米)(P =0.567)。本研究未发现残留效应和不良反应。
在本研究中,局部用倍他米松治疗慢性冻疮并不优于安慰剂。在没有新证据的情况下,不应将局部用倍他米松用于慢性冻疮的治疗。